Marc S Sabatine

Marc S Sabatine

UNVERIFIED PROFILE

Are you Marc S Sabatine?   Register this Author

Register author
Marc S Sabatine

Marc S Sabatine

Publications by authors named "Marc S Sabatine"

Are you Marc S Sabatine?   Register this Author

100Publications

3094Reads

-Profile Views

Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply.

JAMA Cardiol 2019 May 1. Epub 2019 May 1.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2019.1200DOI Listing
May 2019

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.

N Engl J Med 2019 05;380(19):1881-1882

Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1902837
Publisher Site
http://dx.doi.org/10.1056/NEJMc1902837DOI Listing
May 2019

Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

Eur J Heart Fail 2019 Apr 18;21(4):462-470. Epub 2019 Feb 18.

Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458082PMC
April 2019

PCSK9 inhibitors: clinical evidence and implementation.

Authors:
Marc S Sabatine

Nat Rev Cardiol 2019 Mar;16(3):155-165

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41569-018-0107-8
Publisher Site
http://dx.doi.org/10.1038/s41569-018-0107-8DOI Listing
March 2019

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

N Engl J Med 2019 01 10;380(4):347-357. Epub 2018 Nov 10.

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1812389DOI Listing
January 2019

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Circulation 2019 Jan;139(3):366-375

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (B.M.S., E.A.B., A.Q., S.A.M., K.I., M.P.B., C.T.R., M.S.S., S.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038341DOI Listing
January 2019

Opportunities and Challenges in Mendelian Randomization Studies to Guide Trial Design.

JAMA Cardiol 2018 Oct;3(10):967

Deputy Editor, Cardiology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2018.2863DOI Listing
October 2018

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.

JAMA Cardiol 2018 Sep;3(9):823-828

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cardiology.jamanetwork.com/article.aspx?doi=10.1001/j
Publisher Site
http://dx.doi.org/10.1001/jamacardio.2018.2258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233651PMC
September 2018

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

N Engl J Med 2018 09 26;379(12):1107-1117. Epub 2018 Aug 26.

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston (E.A.B., S.D.W., J.K., K.I., A.Q., M.P.B., C.T.R., M.S.S., B.M.S.); the Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas (D.K.M.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); the Department of Medicine, University of Minnesota, Minneapolis (C.L.F.); the Partners Clinical Research Centre, Nassau, Bahamas (C.B.); the Department of Cardiology, Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland (A.B.); Cardiolink Clinical Trials, Monterrey, Mexico (A.G.-C.); McMaster University, Brampton, ON (M.G.), and the Division of Endocrinology and Metabolism, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.) - both in Canada; MedStar Health Research Institute, Hyattsville, MD (N.J.W.); the Cardiology Department, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Eisai, Woodcliff Lake, NJ (T.P., B.F., W.M., C.P., S.D.); National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (A.C.K.); and the Translational Research Institute for Metabolism and Diabetes, Florida Hospital and the Sanford-Burnham Institute, Winter Park (S.R.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1808721DOI Listing
September 2018

WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.

Am J Cardiol 2018 Aug 16. Epub 2018 Aug 16.

Department of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2018.08.020DOI Listing
August 2018

Inflammatory and Cholesterol Risk in the FOURIER Trial.

Circulation 2018 Jul 12;138(2):131-140. Epub 2018 Mar 12.

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (E.A.B., R.P.G., J.-G.P., S.A.M., M.S.S.).

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.0
Publisher Site
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034032DOI Listing
July 2018

DECLARE-TIMI 58: Participants' baseline characteristics.

Diabetes Obes Metab 2018 05 14;20(5):1102-1110. Epub 2018 Feb 14.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13217DOI Listing
May 2018

Pharmacogenetics and the Promise of Personalized Medicine.

Authors:
Marc S Sabatine

JAMA Cardiol 2018 May;3(5):408

Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2018.0586DOI Listing
May 2018

Clinical benefits of evolocumab appear less than hoped - Authors' reply.

Lancet 2018 03;391(10124):934-935

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30529-4DOI Listing
March 2018

Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.

Circulation 2018 02 30;137(7):684-692. Epub 2017 Oct 30.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (I.C., D.A.M., D.L.B., B.S.S., E.L.G., E.B., M.S.S., M.P.B.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031062DOI Listing
February 2018

Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.

J Am Coll Cardiol 2018 Feb;71(5):489-496

Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar and Dutch Network for Cardiovascular Research (WCN), the Netherlands; Department of Cardiology, CWZ Hospital, Nijmegen, the Netherland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2017.11.050DOI Listing
February 2018

Questioning the safety and benefits of evolocumab - Authors' reply.

Lancet Diabetes Endocrinol 2018 01;6(1):11-12

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-8587(17)30403-5DOI Listing
January 2018

Cognitive Function in a Randomized Trial of Evolocumab.

N Engl J Med 2017 11;377(20):1997

Warren Alpert Medical School of Brown University, Providence, RI

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1712102DOI Listing
November 2017

PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity-Reply.

JAMA Cardiol 2017 Oct;2(10):1169

Brigham and Women's Hospital, Cardiovascular Division/TIMI Study Group, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2017.2734DOI Listing
October 2017

Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.

JAMA Cardiol 2017 Sep;2(9):935-936

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2017.2293DOI Listing
September 2017

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic.

Authors:
Marc S Sabatine

Eur Heart J 2017 08;38(29):2256-2258

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehw572DOI Listing
August 2017

Cognitive Function in a Randomized Trial of Evolocumab.

N Engl J Med 2017 08;377(7):633-643

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston (R.P.G., K.I., E.K., M.S.S.); Hôpital Cantonal, Hopitaux Universitaires de Genève, Geneva (F.M.); Cambridge Cognition, Cambridge (K.Z.), and International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London (P.S.S.) - both in the United Kingdom; Amgen, Thousand Oaks, CA (C.K., J.S., H.W., N.H., S.M.W.); Sydney Medical School, NHMRC Clinical Trials Centre, University of Sydney, Sydney (A.K.); Oslo University Hospital, Ullevål, and Medical Faculty, University of Oslo - both in Oslo (T.R.P.); University of Iowa, Iowa City (J.G.R.); and Rhode Island Hospital, Department of Neurology, Alpert Medical School of Brown University, Providence (B.R.O.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1701131
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1701131DOI Listing
August 2017

Evolocumab in Patients with Cardiovascular Disease.

N Engl J Med 2017 08;377(8):787-8

Oslo University Hospital, Oslo, Norway

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1708587DOI Listing
August 2017

Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".

Circulation 2017 07;136(1):120-121

From Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, Perth (G.F.W.); School of Medicine and Pharmacology, University of Western Australia, Perth (G.F.W., D.C.C.); Amgen Inc., Thousand Oaks, CA (R.S., S.M.W.); and TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028790DOI Listing
July 2017

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.

JAMA Cardiol 2017 May;2(5):556-560

Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2016.5395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814982PMC
May 2017

Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.

Thromb Haemost 2017 05 16;117(5):940-947. Epub 2017 Mar 16.

Prof. Robert F. Storey, MD DM FESC, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK, E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1160/TH16-09-0703DOI Listing
May 2017

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

N Engl J Med 2017 05 17;376(18):1713-1722. Epub 2017 Mar 17.

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (M.S.S., R.P.G., S.D.W., S.A.M., J.F.K.); Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (A.C.K.); Amgen, Thousand Oaks, CA (N.H., H.W., T.L., S.M.W.); International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London (P.S.S.); and Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo (T.R.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1615664DOI Listing
May 2017

How We Evaluate Biomarker Studies.

JAMA Cardiol 2017 May;2(5):524

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2017.0291DOI Listing
May 2017

Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.

JAMA 2017 01;317(4):440

TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2016.19064DOI Listing
January 2017

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

N Engl J Med 2016 12;375(22):2144-2153

From the Division of Cardiovascular Medicine, Wayne State University School of Medicine, Detroit (B.A.F.), the Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor (R.D.B.), and Michigan State University, East Lansing (D.R.N.) - all in Michigan; the Departments of Epidemiology and Medicine, College of Public Health, University of Iowa, Iowa City (J.G.R.); the Department of Pharmacological and Biomolecular Sciences, University of Milan and MultiMedica Istituto di Ricovero e Cura a Carattere Scientifico, Milan (A.L.C.); INSERM, Pitié-Salpêtrière University Hospital, Paris (M.J.C.); the Global Genomics Group, Richmond, VA (S.V.); the Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (R.P.G., M.S.S.); the Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom (G.D.S.); and the Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University, Portland (S.F.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1604304
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1604304DOI Listing
December 2016

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice.

Postgrad Med 2016 Oct 14;128 Suppl 1:31-9. Epub 2016 Jul 14.

f MB Clinical Research.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00325481.2016.1208895DOI Listing
October 2016

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.

Circulation 2016 Sep 29;134(10):e123-55. Epub 2016 Mar 29.

Focused Update writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. ACC/AHA Task Force on Clinical Practice Guidelines Liaison. ACC/AHA Representative. Evidence Review Committee Chair. American Society of Anesthesiologists/Society of Cardiovascular Anesthesiologists Representative. American Association for Thoracic Surgery/Society of Thoracic Surgeons Representative. Society for Cardiovascular Angiography and Interventions Representative.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIR.0000000000000404DOI Listing
September 2016

Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction.

JAMA Cardiol 2016 09;1(6):627-8

Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital Heart and Vascular Center, Boston, Massachusetts2Deputy Editor, JAMA Cardiology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2016.2110DOI Listing
September 2016

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).

Circulation 2016 Sep 30;134(12):861-71. Epub 2016 Aug 30.

From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.).

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.0
Publisher Site
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024637DOI Listing
September 2016

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.

JAMA 2016 Sep;316(12):1289-97

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2016.13985DOI Listing
September 2016

Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.

Thromb Haemost 2016 07 24;116(1):69-77. Epub 2016 Mar 24.

Marc S. Sabatine, MD, MPH, Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115, USA, E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1160/TH15-12-0981DOI Listing
July 2016

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.

Circulation 2016 Jul;134(4):304-13

From the TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (E.A.B., M.P.B., E.B., P.H., S.A.M., M.S.S., B.M.S., D.A.M.); South Australian Health and Research Institute, Flinders University and Medical Centre, Adelaide (P.E.A.); Division of Cardiovascular Diseases, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago (R.C.); Department of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (G.M.D.F.); Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion, Haifa, Israel (B.S.L.); and IV Divisione Cardiologia, Azienda Ospedaliera Niguarda Ca' Granda, Milan, Italy (P.A.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019861DOI Listing
July 2016

Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.

Circulation 2016 Jul;134(4):270-85

From Division of Pulmonary and Critical Care Medicine, Department of Medicine (D.N.) and the Cardiovascular Research Center (D.N., S.S., D.S., M.J.K., X.S., M.D.B., J.F.O., L.A.F., R.E.G.), Massachusetts General Hospital, Harvard Medical School, Boston; Broad Institute of MIT and Harvard, Cambridge, MA (E.W.K., H.K., S.A.C., R.E.G.); Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.D.B., M.S.S.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (M.A.F., M.S.S., R.E.G.); Preventive Medicine Section, Department of Medicine, Boston University School of Medicine, MA (R.S.V.); Department of Biostatistics, Boston University School of Public Health, MA (M.G.L.); The National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA (M.G.L.); Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (T.J.W.); and Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (R.E.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021803DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963294PMC
July 2016

Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.

J Am Coll Cardiol 2016 Jun 1;67(23):2732-2740. Epub 2016 Apr 1.

Département Hospitalo-Universitaire-Fibrosis, Inflammation, REmodelling, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université Paris-Diderot, Sorbonne-Paris Cité, and the French Alliance for Cardiovascular Clinical Trials, an F-CRIN network, INSERM U-1148, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2016.03.529DOI Listing
June 2016

Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction.

Authors:
Marc S Sabatine

JAMA 2016 Jun;315(23):2525-6

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2016.6110DOI Listing
June 2016

The Prospects for Cardiovascular Proteomics: A Glass Approaching Half Full.

JAMA Cardiol 2016 06;1(3):245-6

Cardiovascular Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2016.0279DOI Listing
June 2016

The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China.

Am Heart J 2016 May 17;175:193-201.e3. Epub 2015 Apr 17.

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2015.04.014DOI Listing
May 2016

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

Am Heart J 2016 Mar 17;173:94-101. Epub 2015 Dec 17.

Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2015.11.015DOI Listing
March 2016

Advances in the treatment of dyslipidemia.

Authors:
Marc S Sabatine

Cleve Clin J Med 2016 Mar;83(3):181-6

Chairman, TIMI Study Group.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.83gr.16001DOI Listing
March 2016

Oral dual antiplatelet therapy: what have we learnt from recent trials?

Eur Heart J 2016 Jan 6;37(4):344-52. Epub 2015 Aug 6.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehv377DOI Listing
January 2016

Editorial on PEGASUS-TIMI 54.

Eur Heart J Cardiovasc Pharmacother 2015 Oct 23;1(4):217-9. Epub 2015 Jun 23.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ehjcvp/pvv030DOI Listing
October 2015

PCSK9 Inhibitors and Cardiovascular Events.

N Engl J Med 2015 08;373(8):774-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1508222DOI Listing
August 2015